出版社：Association of Clinical Pathologists of Nepal (ACPN)
摘要：Background: To treat symptomatic benign prostatic hyperplasia α 1 -adrenoceptor antagonists with little antagonism at α 1b -adrenoceptor were used to avoid orthostatic hypotension. In benign prostatic hyperplasia tissues α 1D -adrenoceptor are thought to predominate, but in the Japanese experience, either α 1A - or α 1D - adrenoceptor antagonists can alleviate benign prostatic hyperplasia symptoms. We hypothesized that prostatic expression of α 1A - and α 1D -adrenoceptor varies quantitatively between patients. Materials and Methods: We immunohistochemically localized α 1A - and α 1D -adrenoceptor within benign prostatic hyperplasia tissues, and quantitated mRNA expression for these subtypes by real-time quantitative reverse transcription-polymerase chain reaction. Results: Immunohistochemistry detected both subtypes in stromal but not detected epithelial cells. Copy numbers of α 1A -adrenoceptor mRNA in benign prostatic hyperplasia tissue were significantly higher than those of α 1D -adrenoceptor mRNA. Among patients; the ratio of α 1A - to α 1D -adrenoceptor mRNA ranged from 1.0 to 8.4. Conclusion: An ideal therapeutic antagonist for treating benign prostatic hyperplasia symptoms should block both α 1A - and α 1D -adrenoceptor Keywords: Adrenoceptor subtypes; Benign prostatic hyperplasia; Quantitative reverse transcription-polymerase chain reaction DOI: 10.3126/jpn.v1i1.4439 Journal of Pathology of Nepal (2011) Vol.1, 1-7
